FdaApplication
NDA 211765
Identifiers
- fda_app_no: NDA211765
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2019-12-23 |
Revenue by product
UBRELVY
| Period | Revenue |
|---|---|
| Q2 2026 | $392.0M |
| Q1 2026 | $339.0M |
| Q4 2025 | $339.0M |
| Q3 2025 | $354.0M |
| Q2 2025 | $338.0M |
| Q1 2025 | $240.0M |
| Q4 2024 | $303.0M |
| Q3 2024 | $269.0M |
| Q2 2024 | $231.0M |
| Q1 2024 | $203.0M |
| Q4 2023 | $234.0M |
| Q3 2023 | $233.0M |
| Q2 2023 | $196.0M |
| Q1 2023 | $152.0M |
| Q4 2022 | $197.0M |
| Q3 2022 | $160.0M |
| Q2 2022 | $185.0M |
| Q1 2022 | $138.0M |
| Q4 2021 | $183.0M |
| Q3 2021 | $162.0M |
| Q2 2021 | $126.0M |
| Q1 2021 | $81.0M |
| Q4 2020 | $65.0M |
| Q3 2020 | $38.0M |
| Q2 2020 | $22.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| UBRELVY | UBROGEPANT | 100MG | TABLET;ORAL |
| UBRELVY | UBROGEPANT | 50MG | TABLET;ORAL |
2 products